Publications

  1. Wang, S. L. Taylor, J. M. Choo, L. E. Papanicolas, R. Keating, K. Hindmarsh, et al. Carriage and transmission of macrolide resistance genes in patients with chronic respiratory conditions and their close contacts. Chest 2022 DOI: https://doi.org/10.1016/j.chest.2022.01.045
  2. Karunathilaka, S. Halstrom, P. Price, M. Holt, V. P. Lutzky, D. L. Doolan, et al. CD161 expression defines new human γδ T cell subsets Immunity & Ageing 2022 Vol. 19 Issue 1 Pages 11 DOI: 10.1186/s12979-022-00269-w
  3. Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month OpenLabel Extension Clinical Trial K. L. Winthrop, P. A. Flume, R. Thomson, K. C. Mange, D. W. Yuen, M. Ciesielska, et al. Annals of the American Thoracic Society 2021 Vol. 18 Issue 7 Pages 1147-1157 Accession Number: 33326356 DOI: 10.1513/AnnalsATS.202008-925OC
  4. Ruis, J. M. Bryant, S. C. Bell, R. Thomson, R. M. Davidson, N. A. Hasan, et al. Dissemination of Mycobacterium abscessus via global transmission networks Nature Microbiology 2021 DOI: 10.1038/s41564-021-00963-3
  5. Kapur, E. Stroil-Salama, C.-L. Holmes-Liew, P. King, P. Middleton, G. Maguire, et al. Predictors of ‘Frequent Exacerbator’ phenotype in children with bronchiectasis: the first report on children from the Australian Bronchiectasis Registry Respirology 2021 Vol. 26
  6. E. Griffith, R. Thomson, P. A. Flume, T. R. Aksamit, S. K. Field, D. J. Addrizzo-Harris, et al. Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure. Chest 2021 Vol. 160 Issue 3 Pages 831-842
  7. Burke, D. Smith, C. Coulter, S. C. Bell, R. Thomson and J. A. Roberts Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis. Clin Pharmacokinet 2021 Vol. 60 Issue 9 Pages 1081-1102
  8. Winthrop KL, Flume PA, Thomson R, Mange KC, Yuen DW, Ciesielska M, et al. Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial. Annals of the American Thoracic Society. 2021;18(7):1147-57.
  9. Burke A, Smith D, Coulter C, Bell SC, Thomson R, Roberts JA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Myco-bacteria in Cystic Fibrosis. Clinical Pharmacokinetics. 2021.
  10. van Ingen J, Aliberti S, Andrejak C, Chalmers JD, Codecasa LR, Daley CL, et al. Man-agement of drug toxicity in M. avium complex pulmonary disease – an expert panel sur-vey. Clinical Infectious Diseases. 2020.
  11. Thomson RM, Furuya-Kanamori L, Coffey C, Bell SC, Knibbs LD, Lau CL. Influence of climate variables on the rising incidence of nontuberculous mycobacterial (NTM) infec-tions in Queensland, Australia 2001–2016. Science of The Total Environment. 2020;740:139796.
  12. Ruis C, Bryant J, Bell S, R T, Davidson R, Hasan N, et al. Dissemination of Myocbacte-rium abscessus via global transmission networks. Nature Microbiology. 2021.
  13. Griffith DE, Thomson RM, Flume PA, Aksamit TR, Field SK, Addrizzo-Harris DJ, Morimo-to K, Hoefsloot W, Mange KC, Yuen DW, Ciesielska M, Wallace Jnr RJ, van Ingen J, Brown-Elliott B, Coulter C, Winthrop KL, for the CONVERT Study Group.Amikacin Liposome Inhalation Suspension for Refractory MAC Lung Disease: Sustainability and dura-bility of culture conversion and safety of long-term exposure.
  14. Amikacin Liposome Inhalation Suspension for Refractory MAC Lung Disease: Sustaina-bility and durability of culture conversion and safety of long-term exposure.
  15. Kapur N, Stroil-Salama E, Holmes-Liew C-L, King P, Middleton P, Maguire G, et al. Pre-dictors of ‘Frequent Exacerbator’ phenotype in children with bronchiectasis: the first report on children from the Australian Bronchiectasis Registry. Respirology. 2021;26.
  16. Lee A, Smith R, Osadnik C, Burr L, Chang A, Holmes-Liew C-L, et al. The educational needs of people with bronchiectasis in a pulmonary rehabilitation setting. European Res-piratory Journal. 2020;56(suppl 64):76.
  17. Shoemark A, Finch S, Torres A, Elborn S, Ringhausen F, De Soyza A, et al. Sex related differences in aetiology, severity and quality of life in bronchiectasis: data from the EM-BARC, EMBARC-India and Australian bronchiectasis registries. European Respiratory Journal. 2020;56(suppl 64):3335.
  18. Stockwell RE, Leong L, Wheeler N, Bryant J, Wood M, Sherrard L, et al. Alternative transmission pathways of Mycobacterium abscessus group (MABS) respiratory infections. Respirology. 2020;25
  19. Kurz SG, Zha BS, Herman DD, Holt MR, Daley CL, Ruminjo JK, Thomson CC. Summary for Clinicians: 2020 Clinical Practice Guideline Summary for the Treatment of Nontuberculous Mycobacterial Pulmonary Disease. Ann Am Thorac Soc 2020 (In Press)
  20. Ratnatunga C, Lutzky V, Kupz A, Doolan D, Reid D, Bell S, et al. The rise of nontuberculous mycobacterial lung disease. Frontiers in Immunology. 2020.
  21. Aliano D, Thomson R. The epidemiology of extra-pulmonary nontuberculous mycobacterial infection in a pediatric population. Paediatr Infect Dis J. 2020;39(8):671-7.
  22. Visser SK, Bye PTP, Fox GJ, Burr LD, Chang AB, HolmesLiew C-L, et al. Australian adults with bronchiectasis: The first report from the Australian Bronchiectasis Registry. Respiratory Medicine. 2019;155:97-103.
  23. Visser SK, Bye PT, Fox GJ, Burr LD, Chang AB, Holmes-Liew C-L, King P, Middleton PG, Maguire GP, Smith D, Thomson RM, Stroil-Salama E, Britton WJ, Morgan LC. Management of Australian Adults with bronchiectasis in Tertiary Care: evidence- based or access driven? Lung 2019:197(6):803- 810
  24. Thomson R. Inhaled therapies for NTM disease- The way forward? J Cyst Fibrosis. 2019;18:581-3.
  25. Stockwell RE, Chin M, Johnson GR, Wood ME, Sherrard LJ, Ballard E, et al. Transmission of bacteria in bronchiectasis and chronic obstructive pulmonary disease: Low burden of cough aerosols. Respirology. 2019;24(10):980-7.
  26. Holt MR, Kasperbauer SH, Daley CL. Serial sputum induction in nontuberculous mycobacterial pulmonary disease. Eur Respir J 2020; 55: 1902196 [https://doi. org/10.1183/13993003.02196-2019].
  27. Lutzky V, Ratnatunga C, Smith D, Kupz A, Doolan D, Reid D, et al. Anomalies in T cell function are associated with individuals at risk of Mycobacterium abscessus complex infection. Front Immunol. 2018;9(1319).
  28. Timothy, M. Baird; Robyn, Carter; Geoffrey, Eather; et al. Mycobacterium shimoidei a Rare Pulmonary Pathogen, Queensland, Australia. Emerging Infectious Disease journal. Volume: 23 Issue: 11 Pages: 1919, 2017.
  29. Halstrom, S.; Cherry, C. L.; Black, M.; et al. A haplotype spanning P2X7R, P2X4R and CAMKK2 may mark susceptibility to pulmonary non-tuberculous mycobacterial disease. Immunogenetics Volume: 69 Issue: 5 Pages: 287-293, 2017.
  30. Baird, T.; Thomson, R. Mycobacterium Shimoidei – A rare but increasingly recognised pulmonary pathogen. Respirology Volume: 22 Pages: 193, 2017.
  31. Thomson, R.; Donnan, E.; Konstantinos, A. Notification of Nontuberculous Mycobacteria: An Australian Perspective. Annals of the American Thoracic Society Volume: 14 Issue: 3 Pages: 318-323, 2017.
  32. McLeay, S.C.; Harvey, W.M.; Romaniuk, M.N.; et al. Physical comorbidities of post-traumatic stress disorder in Australian Vietnam War veterans. Medical Journal of Australia Volume: 206 Issue: 6 Pages: 251-257, 2017
  33. Halstrom, S.; Thomson, R.; Goullee, H.; et al. Susceptibility to non-tuberculous mycobacterial disease is influenced by rs1518111 in IL10. Human Immunology Volume: 78 Issue: 4 Pages: 391-393, 2017.
  34. Visser, S.; Allan, H.; Burr, L.; et al. The Australian Bronchiectasis Registry – Early Steps in Mapping the impact of Bronchiectasis in Australia and New Zealand. Respirology Volume: 22 Pages: 61, 2017.
  35. Scoleri, G. P.; Choo, J. M.; Leong, L. E. X.; et al. Culture-Independent Detection of Nontuberculous Mycobacteria in Clinical Respiratory Samples. Journal of Clinical Microbiology Volume: 54 Issue: 9 Pages: 2395-2398, 2016
  36. Bryant, Josephine M.; Grogono, Dorothy M.; Rodriguez-Rincon, Daniela; et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science Volume: 354 Issue: 6313 Pages: 751, 2016.
  37. Amran, F. S.; Kim, K.; Lim, A.; et al. Is Pulmonary non-Tuberculous Mycobacterial Disease Linked with a High Burden of Latent Cytomegalovirus? Journal of Clinical Immunology Volume: 36 Issue: 2 Pages: 113-116, 2016.
  38. Thomson, Rachel; Donnan, Ellen; Unwin, Sean. Nontuberculous Mycobacterial Lung Disease. Time to Get a Grip! Annals of the American Thoracic Society Volume: 12 Issue: 10 Pages: 1425-1427, 2015.
  39. Halstrom, S.; Price, P.; Thomson, R. Environmental mycobacteria as a cause of human infection.  International Journal of Mycobacteriology Volume: 4 Issue: 2 Pages: 81-91, 2015.
  40. Law, D. B.; Ellender, C. M.; Thomson, R. M.; et al. Safety of Intravenous Amikacin in the Treatment of Plumonary Non-Tuberculous Mycobacterial Disease. Respirology Volume: 20 Pages: 155, 2015.